Roche has secured approval from the US Food and Drug Administration (FDA) for its cobas Zika test to detect RNA of the Zika virus in human plasma samples.
Intended for the screening of blood and plasma donations in the country, the test is approved for use on the firm’s cobas 6800 / 8800 systems.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The cobas Zika test has been designed as a qualitative in-vitro nucleic acid screening indication to directly detect the virus’ RNA in plasma samples of individual blood donors.
Roche Diagnostics CEO Roland Diggelmann said: “Since its development here at Roche, the cobas Zika test has been used under the investigational new drug application (IND) protocol to screen more than four million blood donations from the United States and Puerto Rico.
“This broad testing has helped to identify and remove over 450 potentially infectious donations from the blood supply, a significant achievement in the rapid response to this global health emergency.”
Initially deployed under the IND protocol in April last year for the screening of blood donations in Puerto Rico, the test was expanded by the end of the year to support donor screening efforts in the US.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWith the cobas 6800 / 8800 systems, which carry out automated sample preparation and PCR amplification and detection, the cobas Zika test is intended to ensure that potentially infected units are not used for blood transfusion.
The cobas 6800 / 8800 software performs automated data management and assigns a result as non-reactive, reactive or invalid.
